Home » Newsletters » BioWorld Science

BioWorld Science

March 12, 2018

View Archived Issues

Sigilon Therapeutics' SIG-003 awarded EMA ATMP designation

iOx Therapeutics receives investment from Portage Biotech

Novel algorithm using proteotoxic biomarkers to discriminate between ASD and healthy subjects

Phase II data presented from the STOP-AKI trial of recAP in sepsis-associated acute kidney injury

Solifenacin oral suspension for pediatric patients approved in Europe

First-in-human results for Progenza in patients with knee osteoarthritis

Polyphor reports outcome of end-of-phase I meeting with FDA on balixafortide

Aradigm submits MAA for Linhaliq in non-cystic fibrosis bronchiectasis

CHRIST University patents new ER-targeting conjugates for cancer

Nanchang Helioeast Pharmaceutical presents new TKIs for cancer

Voyager Therapeutics reports longer-term data from phase Ib study of VY-AADC in Parkinson's disease

Biohaven restructures license agreement with Bristol-Myers Squibb

Medivir discloses novel compounds for RSV infection

IO Biotech collaborates with Merck & Co. to study IO-102 with pembrolizumab for NSCLC

Deinove enters antibiotic research collaboration with Naicons

FDA grants regenerative medicine advanced therapy designation to AmnioFix

BC-007 reduces autoantibodies against G-protein coupled receptors in phase I study

Seattle Genetics' acquisition of Cascadian Therapeutics complete

Kezar Life Sciences initiates phase I/II study of KZR-616 in SLE

Arrowhead opens enrollment in phase I study of ARO-AAT

Immutep and Merck & Co. to collaborate on phase II study of eftilagimod with pembrolizumab

CSL-112 found safe in patients with renal impairment after AMI

Diamyd Medical offers update from DIAGNODE-1 study of Diamyd diabetes vaccine

FDA awards fast track designation to NovaBiotics' Lynovex

Atrial fibrillation burden not reduced by XEN-D0103 in patients with pacemakers

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Deals and an M&A strengthen end-of-year numbers
BioWorld
Two large deals and an acquisition, totaling about $4.64 billion in all, are helping wrap up what’s turning out to be a strong year. Through the first 11 months...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Radiopharm Theranostics’ RAD-101 meets brain metastases endpoints
BioWorld
Radiopharm Theranostics Ltd.’s radiotracer RAD-101 met the primary endpoint in 92% of patients in the phase IIb imaging trial in brain metastases, according to...